A micro-elimination approach to addressing hepatitis C in Turkey

Background: In 2016, WHO passed the Global Health Sector Strategy on Viral Hepatitis (GHSS), calling for its elimination by 2030. Two years later, Turkey approved a strategy to reach the WHO targets. This study reports new national prevalence data, breaks it down by subpopulation, and models scenari...

Descripción completa

Detalles Bibliográficos
Autores: Idilman, Ramazan, Razavi, Homie, Robbins-Scott, Sarah, Akarca, Ulus Salih, Örmeci, Necati, Kaymakoglu, Sabahattin, Aygen, Bilgehan, Tozun, Nurdan, Güner, Rahmet, Hurrem, Lazarus, Jeffrey V.
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2020
País:España
Institución:Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
Repositorio:Recercat. Dipósit de la Recerca de Catalunya
OAI Identifier:oai:recercat.cat:2445/173926
Acceso en línea:https://hdl.handle.net/2445/173926
Access Level:acceso abierto
Palabra clave:Hepatitis C
Vacunes
Vaccines
id ES_8657de4d91f0ceec555f6cf59604f326
oai_identifier_str oai:recercat.cat:2445/173926
network_acronym_str ES
network_name_str España
repository_id_str
spelling A micro-elimination approach to addressing hepatitis C in TurkeyIdilman, RamazanRazavi, HomieRobbins-Scott, SarahAkarca, Ulus SalihÖrmeci, NecatiKaymakoglu, SabahattinAygen, BilgehanTozun, NurdanGüner, RahmetHurremLazarus, Jeffrey V.Hepatitis CVacunesHepatitis CVaccinesBackground: In 2016, WHO passed the Global Health Sector Strategy on Viral Hepatitis (GHSS), calling for its elimination by 2030. Two years later, Turkey approved a strategy to reach the WHO targets. This study reports new national prevalence data, breaks it down by subpopulation, and models scenarios to reach HCV elimination. Methods: Literature was reviewed for estimates of HCV disease burden in Turkey. They were discussed with stakeholders and used as inputs to develop a disease burden model. The infected population was estimated by sequelae for the years 2015–2030. Three scenarios were developed to evaluate the disease burden in Turkey: a Base 2017 scenario, representing the current standard of care in Turkey; an increased treatment scenario, representing the impact of improved access to DAAs; and a WHO targets scenario, which meet the WHO GHSS viral hepatitis targets of a 65% reduction in mortality and 90% diagnosis rate of the infected population by 2030. Results: At the beginning of 2017, 271,000 viremic infections were estimated. Of these, 58,400 were diagnosed and 10,200 treated. Modelling results showed that, with the current treatment paradigm in Turkey, by 2030 the total number of viremic HCV infections would decline by 35%, while liver-related deaths, hepatocellular carcinoma (HCC), and decompensated cirrhosis would decrease by 10–25%. In the increased treatment scenario, by 2030 viremic HCV infections would decrease by 50%; liver-related deaths, HCC and decompensated cirrhosis would decrease by 45–70%. In the WHO targets scenario, HCV infections would decrease by 80%; sequelae would decrease by 80–85%. Data on disease burden in micro-elimination target subpopulations are largely unavailable. Conclusions: To meet the WHO Global Health Sector Strategy targets for the elimination of HCV, Turkey needs to increase treatment. Better data are needed as well as countrywide access to DAAs.BioMed Central2021202120202021info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersion9 p.application/pdfapplication/pdfhttps://hdl.handle.net/2445/173926Articles publicats en revistes (ISGlobal)reponame:Recercat. Dipósit de la Recerca de Catalunyainstname:Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)InglésReproducció del document publicat a: http://dx.doi.org/10.1186/s12913-020-5019-8BMC Health Services Research, 2020, vol. 20http://dx.doi.org/ 10.1186/s12913-020-5019-8cc by (c) Idilman et al., 2020http://creativecommons.org/licenses/by/3.0/es/info:eu-repo/semantics/openAccessoai:recercat.cat:2445/1739262026-05-29T05:05:01Z
dc.title.none.fl_str_mv A micro-elimination approach to addressing hepatitis C in Turkey
title A micro-elimination approach to addressing hepatitis C in Turkey
spellingShingle A micro-elimination approach to addressing hepatitis C in Turkey
Idilman, Ramazan
Hepatitis C
Vacunes
Hepatitis C
Vaccines
title_short A micro-elimination approach to addressing hepatitis C in Turkey
title_full A micro-elimination approach to addressing hepatitis C in Turkey
title_fullStr A micro-elimination approach to addressing hepatitis C in Turkey
title_full_unstemmed A micro-elimination approach to addressing hepatitis C in Turkey
title_sort A micro-elimination approach to addressing hepatitis C in Turkey
dc.creator.none.fl_str_mv Idilman, Ramazan
Razavi, Homie
Robbins-Scott, Sarah
Akarca, Ulus Salih
Örmeci, Necati
Kaymakoglu, Sabahattin
Aygen, Bilgehan
Tozun, Nurdan
Güner, Rahmet
Hurrem
Lazarus, Jeffrey V.
author Idilman, Ramazan
author_facet Idilman, Ramazan
Razavi, Homie
Robbins-Scott, Sarah
Akarca, Ulus Salih
Örmeci, Necati
Kaymakoglu, Sabahattin
Aygen, Bilgehan
Tozun, Nurdan
Güner, Rahmet
Hurrem
Lazarus, Jeffrey V.
author_role author
author2 Razavi, Homie
Robbins-Scott, Sarah
Akarca, Ulus Salih
Örmeci, Necati
Kaymakoglu, Sabahattin
Aygen, Bilgehan
Tozun, Nurdan
Güner, Rahmet
Hurrem
Lazarus, Jeffrey V.
author2_role author
author
author
author
author
author
author
author
author
author
dc.subject.none.fl_str_mv Hepatitis C
Vacunes
Hepatitis C
Vaccines
topic Hepatitis C
Vacunes
Hepatitis C
Vaccines
description Background: In 2016, WHO passed the Global Health Sector Strategy on Viral Hepatitis (GHSS), calling for its elimination by 2030. Two years later, Turkey approved a strategy to reach the WHO targets. This study reports new national prevalence data, breaks it down by subpopulation, and models scenarios to reach HCV elimination. Methods: Literature was reviewed for estimates of HCV disease burden in Turkey. They were discussed with stakeholders and used as inputs to develop a disease burden model. The infected population was estimated by sequelae for the years 2015–2030. Three scenarios were developed to evaluate the disease burden in Turkey: a Base 2017 scenario, representing the current standard of care in Turkey; an increased treatment scenario, representing the impact of improved access to DAAs; and a WHO targets scenario, which meet the WHO GHSS viral hepatitis targets of a 65% reduction in mortality and 90% diagnosis rate of the infected population by 2030. Results: At the beginning of 2017, 271,000 viremic infections were estimated. Of these, 58,400 were diagnosed and 10,200 treated. Modelling results showed that, with the current treatment paradigm in Turkey, by 2030 the total number of viremic HCV infections would decline by 35%, while liver-related deaths, hepatocellular carcinoma (HCC), and decompensated cirrhosis would decrease by 10–25%. In the increased treatment scenario, by 2030 viremic HCV infections would decrease by 50%; liver-related deaths, HCC and decompensated cirrhosis would decrease by 45–70%. In the WHO targets scenario, HCV infections would decrease by 80%; sequelae would decrease by 80–85%. Data on disease burden in micro-elimination target subpopulations are largely unavailable. Conclusions: To meet the WHO Global Health Sector Strategy targets for the elimination of HCV, Turkey needs to increase treatment. Better data are needed as well as countrywide access to DAAs.
publishDate 2020
dc.date.none.fl_str_mv 2020
2021
2021
2021
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv https://hdl.handle.net/2445/173926
url https://hdl.handle.net/2445/173926
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.relation.none.fl_str_mv Reproducció del document publicat a: http://dx.doi.org/10.1186/s12913-020-5019-8
BMC Health Services Research, 2020, vol. 20
http://dx.doi.org/ 10.1186/s12913-020-5019-8
dc.rights.none.fl_str_mv cc by (c) Idilman et al., 2020
http://creativecommons.org/licenses/by/3.0/es/
info:eu-repo/semantics/openAccess
rights_invalid_str_mv cc by (c) Idilman et al., 2020
http://creativecommons.org/licenses/by/3.0/es/
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv 9 p.
application/pdf
application/pdf
dc.publisher.none.fl_str_mv BioMed Central
publisher.none.fl_str_mv BioMed Central
dc.source.none.fl_str_mv Articles publicats en revistes (ISGlobal)
reponame:Recercat. Dipósit de la Recerca de Catalunya
instname:Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
instname_str Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
reponame_str Recercat. Dipósit de la Recerca de Catalunya
collection Recercat. Dipósit de la Recerca de Catalunya
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869412366978908160
score 15.812455

Similares en LA Referencia